Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
AMAmylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ Global Select · Currency in USD
$27.20 ▼ -1.37 (-4.80%)
At close: Oct 23, 4:00 PM ET. Market closed.
$27.25 ▲ +0.05 (+0.18%)
After hours: Oct 23, 7:33 PM ET

Summary

Previous Close
$28.57
Open
$28.46
Day's Range
$27.06 – $28.46
52 Week Range
$10.83 – $41.14
Volume
1,158,753
Avg. Volume
2,132,193
Market Cap
$3.41B
Beta (5Y Monthly)
-0.21
PE Ratio (TTM)
--
EPS (TTM)
-$1.37
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
$1.68 (6.18%)
Ex-Dividend Date
Mar 28, 2018
1y Target Est
$52.20

Profile: Amylyx Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
136
CEO
Joshua Cohen
Website
amylyx.com

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.38 · Revenue est. $59.43K
DateEst.Actual
Aug 6, 2026-$0.36-$0.39Miss
May 7, 2026-$0.34-$0.37Miss
Mar 3, 2026-$0.31-$0.30Beat
Nov 6, 2025-$0.43-$0.37Beat
Aug 7, 2025-$0.44-$0.46Miss
May 8, 2025-$0.45-$0.42Beat

Analyst view

Consensus price target
$52.20 ▲ +91.9%
Range $42.00 – $57.00
Rating: Buy
Buy 91% · Hold 9% · Sell 0%

Get free alerts on AMLX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.